Analysts Set AstraZeneca PLC (LON:AZN) PT at £104.12

Shares of AstraZeneca PLC (LON:AZN) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is £104.12 ($131.99).

Several equities analysts have recently commented on AZN shares. JPMorgan Chase & Co. restated an “overweight” rating and set a £140 ($177.46) price target on shares of AstraZeneca in a research note on Thursday, November 7th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Berenberg Bank reiterated a “buy” rating and set a £150 ($190.14) price objective on shares of AstraZeneca in a research note on Monday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 ($139.43) price objective on shares of AstraZeneca in a research note on Tuesday, September 3rd.

Insider Buying and Selling

In related news, insider Pascal Soriot acquired 20,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were purchased at an average cost of £102.03 ($129.33) per share, with a total value of £2,040,600 ($2,586,639.62). Also, insider Michel Demare purchased 2,000 shares of the company’s stock in a transaction on Friday, September 13th. The shares were purchased at an average price of GBX 118 ($1.50) per share, for a total transaction of £2,360 ($2,991.51). 0.04% of the stock is owned by company insiders.

AstraZeneca Stock Down 0.6 %

Shares of LON AZN opened at GBX 9,915 ($125.68) on Friday. The stock has a 50 day moving average price of £115.70 and a 200 day moving average price of £121.20. The firm has a market capitalization of £153.68 billion, a price-to-earnings ratio of 3,147.62, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a 52-week low of GBX 9,461 ($119.93) and a 52-week high of £133.88 ($169.70). The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.